Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats

Epilepsy Research

Volumn 58, Issue 2-3, 2004, Pages 85-91

  Potschka, Heidrun ^a   Baltes, Steffen ^a   Löscher, Wolfgang ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Epilepsy; Multidrug resistance proteins; P glycoprotein; Probenecid; Verapamil

Indexed keywords

ETIRACETAM; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; PROBENECID; VERAPAMIL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG UPTAKE; EPILEPSY; EXTRACELLULAR FLUID; IN VIVO CULTURE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; PIRACETAM; PROBENECID; RATS; RATS, WISTAR; VERAPAMIL;

EID: 2142773119     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2003.12.007     Document Type: Article

References (36)

1. Aronica E., Gorter J.A., Jansen G.H., van Veelen C.W., van Rijen P.C., Leenstra S., Ramkema M., Scheffer G.L., Scheper R.J., Troost D. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors. Neuroscience. 118:2003;417-429
2. Benveniste, H., Hansen, A., 1991. Robinson, T.E., Justice, J.B. (Eds.), Microdialysis in the Neurosciences. Elsevier, Amsterdam, pp. 81-102.
3. Betts T., Yarrow H., Greenhill L., Barrett M. Clinical experience of marketed Levetiracetam in an epilepsy clinic-a one year follow up study. Seizure. 12:2003;136-140
4. Borst P., Evers R., Kool M., Wijnholds J. The multidrug resistance protein family. Biochim. Biophys. Acta. 1461:1999;347-357
5. Borst P., Evers R., Kool M., Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92:2000;1295-1302
6. Dombrowski S.M., Desai S.Y., Marroni M., Cucullo L., Goodrich K., Bingaman W., Mayberg M.R., Bengez L., Janigro D. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia. 42:2001;1501-1506
7. Dooley M., Plosker G.L. Levetiracetam. A review of its adjunctive use in the management of partial onset seizures. Drugs. 60:2000;871-893
8. Gerk P.M., Vore M. Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J. Pharmacol. Exp. Ther. 302:2002;407-415
9. Haria M., Balfour J.A. Levetiracetam. Cns. Drugs. 7:1997;159-164
10. Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia. 42(Suppl. 4):2001;13-18
11. Lee G., Dallas S., Hong M., Bendayan R. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol. Rev. 53:2001;569-596
12. Leppik, I.E., 2002. Levetiracetam: clinical use. In: Levy, R.H., Mattson, R.H., Meldrum, B.S., Perucca, E. (Eds.), Antiepileptic Drugs. Fifth edition, Lippincott Williams & Wilkins, Philadelphia, pp. 433-441.
13. Löscher W. Animal models of drug-resistant epilepsy. Novartis. Found. Symp. 243:2002a;149-159. (discussion 159-6)
14. Löscher W. Current status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol. Sci. 23:2002;113-118
15. Löscher W., Frey H.-H. Kinetics of penetration of common antiepileptics drugs into cerebrospinal fluid. Epilepsia. 25:1984;346-352
16. Löscher W., Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol. 232:1993;147-158
17. Löscher W., Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther. 301:2002;7-14
18. Löscher W., Schmidt D. New horizons in the development of antiepileptic drugs. Epilepsy Res. 50:2002;3-16
19. Osterberg T., Norinder U. Theoretical calculation and prediction of P-glycoprotein-interacting drugs using MolSurf parametrization and PLS statistics. Eur. J. Pharm. Sci. 10:2000;295-303
20. Patsalos, P.N., 2002. Levetiracetam: chemistry, biotransformation, pharmacokinetics, and drug interactions. In: Levy, R.H., Mattson, R.H., Meldrum, B.S., Perucca, E. (Eds.), Antiepileptic Drugs. Fifth Edition, Lippincott Williams & Wilkins, Philadelphia, pp. 428-432.
21. Potschka H., Fedrowitz M., Löscher W. P-Glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport. 12:2001;3557-3560
22. Potschka H., Fedrowitz M., Löscher W. P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci. Lett. 327:2002;173-176
23. Potschka H., Fedrowitz M., Löscher W. Multidrug resistance protein MRP2 contributes to blood- brain barrier function and restricts antiepileptic drug activity. J. Pharmacol. Exp. Ther. 306:2003;124-131
24. Potschka H., Löscher W. Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain. Neuroreport. 12:2001a;2387-2389
25. Potschka H., Löscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia. 42:2001;1231-1240
26. Sammes, P.G., Taylor, J.B., 1990. The comprehensive medicinal chemistry, vol. 6 (version 2002.1), Pergamon Press, London.
27. Scheffer G.L., Scheper R.J. Drug resistance molecules: lessons from oncology. Novartis. Found. Symp. 243:2002;19-31
28. Seelig A. How does P-glycoprotein recognize its substrates? Int. J. Clin. Pharmacol. Ther. 36:1998;50-54
29. Seelig A., Blatter X.L., Wohnsland F. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison. Int. J. Clin. Pharmacol. Ther. 38:2000;111-121
30. Shen, D.D., 1999. In: Löscher, W. (Ed.), Valproate: Absorption, Distribution, and Excretion. Valproate, Birkhäuser, Basle, pp. 77-90.
31. Silverman J.A. Multidrug-resistance transporters. Pharm. Biotechnol. 12:1999;353-386
32. Sisodiya S. Drug resistance in epilepsy: not futile, but complex? Lancet Neurol. 2:2003;331
33. Sisodiya S.M., Lin W.-R., Harding B.N., Squier M.V., Keir G., Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain. 125:2002;22-31
34. Stouch T.R., Gudmundsson O. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv. Drug Deliv. Rev. 54:2002;315-328
35. Tishler D.M., Weinberg K.T., Hinton D.R., Barbaro N., Annett G.M., Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia. 36:1995;1-6
36. Tong X., Patsalos P.N. A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain. Br. J. Pharmacol. 133:2001;867-874